维普期刊资源整合服务平台（V6.5）

28篇 您的检索式：作者名="Chaft"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Association of kras and egfr mutations with survival in patients with advanced lung adenocarcinomas显示文摘	Johnson ML Sima CS Chaft J	2013	Cancer2013，119，：	1
2	Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers:proposal for the use of major pathological response as a surrogate endpoint显示文摘	Hellmann MD Chaft JE William WN Jr	2014	Lancet Oncol2014，15，1：	1
3	EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics 显示文摘	Arcila ME Nafa K Chaft JE	2013	Mol Cancer Ther2013，12，2：	1
4	ALK-rear- ranged lung cancer: adenosquamous lung cancer mas-querading as pure squamous carcinoma显示文摘	Chaft JE Rekhtman N Ladanyi M	2012	J Thorac Oncol2012，7，4：	1
5	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to Erlotinib or Gefitinib:Implications for clinical trial design显示文摘	Chaft JE Oxnard GR Sima CS		0，，19：	1
6	Pathological response after neoadjuvant chemotherapy in resectable non small cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint显示文摘	Hellmann MD Chaft JE William WN	2014	Lancet Oncol2014，15，：	1
7	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib:implications for clinical trial design显示文摘	Chaft JE Oxnard GR Sima CS		0，，19：	1
8	SELECT: A multicenter phase 1I trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC显示文摘	Pennell NA Neal JW Chaft JE	2014	J Clin Oncol2014，32，15：	1
9	Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab 显示文摘	Hellmann MD Chaft JE Rusch V	2013	Cancer Chemoth Pharm2013，72，2：	1
10	Incorporation of crizotinib into the NCCN guidelines 显示文摘	Riely GJ Chaft JE Ladanyi M	2011	J Nail Compr Canc Netw2011，9，12：	1
11	Prevalence, clinicopathologic associations and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas显示文摘	Arcila ME Chaft JE Nafa K	2012	Clin Cancer Res2012，18，18：	1
12	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design显示文摘	Chaft jE Oxnard GR Sima CS	2011	Clin Cancer Res2011，17，19：	1
13	A multicenter phase II trial of adjuvant Erlotinib in resected early-stage EGFR mutation-positive NSCLC显示文摘	Pennell NA Neal JW Chaft JE	2014	J Clin Oncol2014，32，5：	1
14	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design显示文摘	Chaft JE Oxnard GR Sima CS	2011	C/in Cancer Res2011，17，19：	1
15	Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers显示文摘	Chaft J E Rekhtman N Sima C S	2013	Cancer chemotherapy and pharmacology2013，72，4：	1
16	Phase ]I study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers显示文摘	Chaft JE Rekhtman N Sima CS	2013	Cancer Chemother Pharmacol2013，72，4：	1
17	Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers显示文摘	Jamie E. Chaft Valerie Rusch Michelle S. Ginsberg Paul K. Paik David J. Finley Mark G. Kris Katharine A.R. Price Christopher G. Azzoli Matthew G. Fury Gregory J. Riely Lee M. Krug Robert J. Downey Manjit S. Bains Camelia S. Sima Nabil Rizk William D. Trav	2013	Journal of Thoracic Oncology2013，，8：	1
18	Egfr exon 20 insertion mutations in lung adenocarcinomas:prevalence,molecular heterogeneity,and clinicopathologic characteristics显示文摘	Arcila ME Nafa K Chaft JE	2013	Mol Cancer Ther2013，12，：	1
19	Disease flare after tyro-sine kinase inhibitor discontinuation in patients with EGFR-mu-tant lung cancer and acquired resistance to erlotinib or gefitinib :implications for clinical trial design显示文摘	Chaft JE Oxnard GR Sima CS	2011	Clin Cancer Res2011，17，19：	1
20	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib显示文摘	Chaft JE Oxnard GR Sima CS		0，，19：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示